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Abstract
In this paper we suggest a new Bayesian approach to network meta-analysis for the case of
discrete multiple outcomes. The joint distribution of the discrete outcomes is modeled
through a Gaussian copula with binomial marginals. The remaining elements of the hierar-
chial random effects model are specified in a standard way, with the logit of the success
probabilities given by the sum of a baseline log-odds and random effects comparing the log-
odds of each treatment against the reference and having a Gaussian distribution centered
at the vector of pooled effects. An adaptive Markov Chain Monte Carlo algorithm is devised
for running posterior inference. The model is applied to two datasets from Cochrane
reviews, already analysed in two papers so to assess and compare its performance. We
implemented the model in a freely available R package called netcopula.
Introduction
In the last decades, as the need of evidence based techniques in medical research and clinical
practice has been more and more recognized, the use of meta-analysis, introduced with a high
level of debate, has become widespread. Nowadays, areas of application of meta-analysis
extend beyond medicine and health, being widely used in both natural and social sciences. See
[1] for a critical review of the main methodological developments in meta-analysis. Tradition-
ally, meta-analytic techniques make it possible to summarize evidence provided by several
studies comparing the same treatments and considering in general one outcome at time. The
basic methods combine study-specific treatment effect estimates under a fixed effect or a ran-
dom effect model (see [2] and [3]). Study specific covariates and individual patients data can
be incorporated as well (see for IPD meta-analysis among others [4–6] and [7]). Bayesian
methods are widely used, making it possible to allow for all parameter uncertainty in the
model, to include all relevant information and to extend the models to accommodate more
complex scenarios. Advantages of the Bayesian approach are discussed and reviewed in several
papers and books, see among others [8] and [9].
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Meta-analytic techniques have been developed in the recent years along several directions.
In the present work, we focus on one of the most recent development, multiple outcomes net-
work meta-analysis. Network meta-analysis in the past few years has become increasingly pop-
ular and its advantages and disadvantages are discussed in several published articles, see
among others [10–14] and [15]. In particular [16] provide a complete and detailed review of
network meta-analysis techniques. Network meta-analysis makes it possible to combine both
direct and indirect evidence provided by different studies with respect to different treatments.
The main challenge is to use the totality of trial evidence to determine an internally consistent
set of estimated treatment effects between all treatments, while respecting randomization. As
long as the included trials and treatments form a connected network, network meta-analysis
allows to borrow strength across treatments in the estimation of relative effect sizes. Full-
fledged ranking of all considered treatments can be also obtained. Several methods for running
univariate network meta-analysis have been proposed and coded in statistical packages. How-
ever, there are relatively few attempts to extend these methods to the multivariate setting.
The need of multiple outcomes network meta-analytic techniques stems from the fact that
often studies report several outcomes, that in general are correlated. Such correlation arises
when several outcomes are measured on the same participants, when one event is nested in
another (as in the case of disease survival nested in total survival) or when outcomes are mea-
sured repeatedly on the same participants. The outcomes correlation entails a correlation of
the treatments effect, which is clearly neglected if separate univariate network meta-analyses
are run for each outcome. Multiple outcomes network meta-analysis makes it possible to
account for such within-study correlation of the treatment effects so to simultaneously borrow
strength across treatments and outcomes. In this way, more studies contribute towards each
outcome and treatment comparison. Indeed, summary results for each outcome depend on
correlated results from other outcomes, and summary results for each treatment comparison
incorporate indirect evidence from related treatment comparisons, in addition to any direct
evidence.
Multiple outcomes network meta-analysis faces the same issues that multiple outcomes
meta-analysis addresses, but in a more complicated setting, see [17] and [18] for an overview
of advantages and disadvantages of multiple outcomes techniques. We can identify two main
challenges. The first stems from the fact that while studies report estimates and standard errors
of the treatments relative effect for each outcome, rarely the corresponding covariance matrix
is provided. In multiple outcomes meta-analysis, a common choice is to assume that the
within-study covariance is known and to focus on the estimation of the between-study covari-
ance matrix. In a frequentist approach the entries of such matrix are estimated resorting to
maximum likelihood techniques as in [19] or restricted maximum likelihood techniques as in
[20]. Method of moments techniques are used as well, [21] and [22] suggest a multivariate gen-
eralization of the DerSimonian and Laird’s methodology. [23] suggest a structural equation
modeling approach (see [24] for a review on the use of such approach in meta-analysis). The
within-study correlation coefficients are then imputed on the basis of individual patients data,
when available for similar studies. When individual patients data are not available, plausible
values can be assumed on the basis of clinical considerations as in [25]. As well empirical cor-
relations can be used as in [20]. [26] use delta methods to approximate the within-study corre-
lation on the basis of information on the outcomes correlation. [27] suggest a Bayesian
approach to multiple outcome meta-analysis, where the within study variances are assumed to
be known and simplifying assumptions are made on the correlations so to reduce the number
of parameters. Noninformative priors are assigned to such correlations. [28] use external
sources of information to construct informative priors for both within-study correlations and
the between-study covariance matrix.
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The second issue to be addressed in a multivariate generalization of network meta-analytic
techniques comes from the fact that not all studies report results on all the considered out-
comes. In multiple outcomes meta-analysis, the missing outcomes issue is addressed relying
on traditional imputation and data augmentation techniques both in a frequentist and a Bayes-
ian approach ([29, 30]). In a Bayesian approach [26] express the likelihood as a product of
marginal distributions over reported outcomes following the approach suggested by Glester
and Olkin in [31]. Such techniques make it possible to borrow strength across outcomes and
this, as pointed out by [32], reduces the impact of a selective non reporting of the outcomes on
the pooled treatment effect estimates.
In this work we adopt a contrast-based perspective to estimate the treatment effects in a net-
work meta-analysis, see [33, 34]. Contrast-based models currently represent the most popular
methodology in the network meta-analysis literature. However, another approach, called arm-
based, has also been recently advanced (see [35–38]). In contrast-based models, a baseline
treatment is defined for each study and the focus of the analysis is on the estimation of the rela-
tive treatment effects (for example using log odds ratios, or another suitable metric). In this
context, the baseline effects are treated as nuisance parameters and they are usually modeled
with noninformative prior distributions. This implies that absolute treatment effects cannot be
directly obtained unless a reference treatment absolute effect is first estimated using informa-
tion that are external to the model see among others [39]. On the contrary, arm-based models
aim to model the absolute effect of each treatment in a study (for example using the log odds)
and the relative treatment effects are then constructed from the arm estimates. Contrast-based
models are usually advocated as more theoretically grounded compared to the arm-based
approach because the latter discards the randomization structure of the evidence. Moreover,
arm-based models are more likely to provide biased estimates of relative treatment effects with
increased posterior variances, and they often show a slower convergence especially when some
treatments are only included in few studies. On the contrary, arm-based models are more
advantageous because they can also incorporate the information provided by single-arm stud-
ies. For more details on the pros and cons of the two approaches see [40] and the discussion
rejoinder by [41], while for a more technical comparison between arm-based and contrast-
based models for network meta-analysis we suggest the recent work by [42].
In this paper we present a new approach to network meta-analysis in the case of discrete
multiple outcomes. The model we suggest is a Bayesian hierarchical random effects model that
is based on a Gaussian copula likelihood, which allows to incorporate the estimation of within-
study variances and correlations. Our approach draws on and generalizes the method sug-
gested by [43] based on a Clayton copula model. However the switch from a Clayton copula
model to a Gaussian copula model is not straightforward due to the implications in terms of
computational problems to be addressed. Indeed in the case of Clayton copula model the cor-
relation between outcomes is modeled through a single univariate parameter, while in the case
of a Gaussian copula model the association is modeled through a correlation matrix. Posterior
inferences are based on a latent variables adaptive Markov Chain Monte Carlo algorithm, that
draws on the suggestions by [44] and [45] for copula regression models and by [46] for the
simulation of correlation matrices. The uncertainty due to the missingness problem is
addressed and accounted for through a posterior based imputation of missing outcomes at
each stage of the algorithm. All codes, data and examples are available in a R package called
netcopula, that can be freely downloaded from the following public repository https://
github.com/sergioventurini/netcopula.
The set-up of the paper is as follows. Section 2 provides a description of the suggested
model and of the MCMC algorithm devised for running posterior inferences. In Section 3 two
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applications of the model are provided with a comparison with other two different approaches.
Section 4 provides a discussion with final conclusions.
Method
Introduction
Copula models have become widely used in all applied fields since they make it possible to
split the specification of a multivariate model into two parts: the marginal distributions on one
side and the dependence structure on the other side. In this way, any univariate distribution
can be used for modelling the marginal behavior of the considered variables, which can be dis-
crete and continuous. Moreover, marginal distributions belonging to different families can be
selected, ensuring a higher flexibility with respect to a traditional modeling with multivariate
distributions. The dependency across the variables is then modelled through a copula function
that “glues together” the marginal distributions.
In the following, we briefly review the copula based approach for the case of two variables,
Y1 and Y2, with marginal cumulative distributions F1 and F2 respectively. We want to obtain a
bivariate distribution for the vector (Y1, Y2) having these two margins. Sklar ([47]) proved that
we can always find a function C such that
FðY1 ¼ y1;Y2 ¼ y2Þ ¼ CðF1ðy1Þ; F2ðy2ÞÞ ð1Þ
where C(y1, y2) is the joint distribution function for a pair of bivariate uniform random vari-
ables. Sklar called C copula function and showed three relevant properties (see [48] for a
detailed introduction to copula models). The distribution in Eq (1) is constructed from the
marginal distributions F1 and F2, while the role of the copula function is to determine the
dependence between Y1 and Y2. If the marginal distributions are continuous, differentiating
Eq (1) gives the joint density
f ðy1; y2Þ ¼ cðF1ðy1Þ; F2ðy2ÞÞf1ðyÞf2ðyÞ ð2Þ
where c(F1(y1), F2(y2)) is the copula density. Eq (2) shows that the copula density controls the
level of dependence between Y1 and Y2. The copula function does not determine the distribu-
tion of the margins. It merely determines the dependence between the two random variables.
There are many copula functions, one of the most popular is the Gaussian copula. In the con-
tinuous case a useful way to think at the copula method is that, based on the probability inte-
gral transformation on each margin, the original variables are each transformed into uniform
random variables Uj = Fj(Yj). Indeed no matter is the marginal distribution Fj, Uj has a uni-
form distribution and the dependency between the original variables carries through to the
transformed uniform distributions. In this way, assuming a copula model as in Eq (1) for the
pair (Y1, Y2) reduces to considering the following model
Yj ¼ F  1j ðUjÞ j ¼ 1; 2
ðU1;U2Þ � Cðu1; u2Þ
In the case of discrete marginal distributions, the marginal are steps function, we define Uj
as associated with the variable Yj through the following inequality
FjðYj   1Þ < Uj < FjðYjÞ
Nevertheless this still ensures Yj is uniformly distributed in the interval (0, 1). The method
can be easily generalized to the case of more than two variables.
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Model specification
We consider a sample of n multi-arm randomized trials and let yik denote the vector of the
number of times each of M outcomes is observed in study i for treatment k, that is yik = (yik1,
. . ., yikM)>, k 2 T i ¼ f1; . . . ; aig, where k 2 T i is the set of treatments compared in study i,
with the treatment labelled as 1 representing the control (i.e. the baseline) treatment in study i
whose efficacy is compared with that of the remaining (ai − 1) treatments. Note that the term
“treatment 1” may refer to distinct treatments in the different studies. We suggest to model yik
as the realization of a multivariate discrete random variable Yik, i = 1, . . ., n and k 2 T i, with
distribution built from a Gaussian copula with binomial margins. We assume that for each
study i, each arm k and each outcome m
yikm ¼ F  1ikmðΦðxikmÞ j nik; pikmÞ
where F  1ikmð� j nik; pikmÞ is the inverse cumulative distribution function of a binomial random
variable with parameters nik and pikm, nik is the number of patients randomized to arm k in
study i, pikm the treatment-specific probability of an outcome of type m in study i and xikm is
the m-th component of vector xik, that is the realization of a random vector having a multivari-
ate Gaussian distribution with a arm-specific correlation matrix, Γk. As previously empha-
sized, Fikm as the cumulative distribution function of a discrete random variable is a step
function, therefore its inverse is a many-to-one function. This indeed complicates the calcula-
tions as compared to the continuous case (see [49]). The variables xikm are latent, not observed
variables to be associated with each yikm. The logistic transformations of the treatment-specific
probabilities logit ðpikmÞ ¼ yikm are modelled for k 2 T i ¼ f1; . . . ; aig, as follows
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where, μi = (μi1, . . ., μiM)> denotes the vector of study-specific baseline effects and δik = (δik1,
. . ., δikM)
> indicates the trial-specific log-odds ratios of treatment k 2 T  i relative to the base-
line treatment (i.e. treatment 1) in study i.
Finally, we assume that the random effects have a multivariate normal distribution
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where ti1 denotes the baseline treatment in study i, tij is the j-th treatment compared in study i
and dj,k = (dj,k,1, . . ., dj,k,M)> represents the vector of pooled effects (across trials) of treatment
k relative to treatment j. The dj,k are usually the main quantities of interest in a meta-analysis.
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The consistency equations
dti1 ;tij;m ¼ dr;tij;m   dr;ti1 ;m ð4Þ
where r identifies a treatment chosen as reference, ensure that the correct treatment compari-
son is used in the network meta-analysis (see [33] and [50]). Note that to guarantee consis-
tency, it is also required that dr,r,1 = � � � = dr,r, M = 0.
The matrix S in Eq (3) contains the variances of the random effect δi,k, j for each treatment
k 2 2, . . ., ai and each outcome m = 1. . ., M, and all possible covariances between any two ran-
dom effects. As the pooled treatment effects, it is common to all studies and for this reason
commonly referred to as a matrix that defines the between-study covariance structure, in
opposition to the Γi that models the within-study correlation structure across outcomes. To
keep the number of parameters manageable and to allow identifiability of S, we follow [51]and
make the following simplifying assumption
Σ ¼
ΣM
1
2
ΣM � � �
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ΣM � � �
1
2
ΣM
. .
. ..
.
ΣM
0
B
B
B
B
B
B
B
B
B
B
B
@
1
C
C
C
C
C
C
C
C
C
C
C
A
where
ΣM ¼
s2
1
� � � r1Ms1sM
. .
. ..
.
s2M
0
B
B
B
B
@
1
C
C
C
C
A
;
describes the common between-study covariance structure. In this way, we assume that the
variances and covariances of the random effects for each treatment comparison are the same
and differ only with respect to the considered outcome. Moreover, such homogeneity assump-
tion along with the structural relationships between the dj,k within trial i imply that the
between-arm correlations are assumed to be all equal to 0.5 (see [52]). These correlations
between the treatment differences come from the fact that all differences are taken relative to
the same control arm, that is, they depend on the same trial baseline effect μi.
Priors choice
As for the prior assignment, proper priors are selected and we specify them in the application
so to be vague. The study-specific baseline effects μi = (μi1, . . ., μiM) are assumed to be indepen-
dent and distributed according to a normal distribution with mean zero and variance s2
m
. As
well the pooled (across trial effects) dr,q = (dr,q,1, . . ., dr,q, M) are assumed to be independent
and identically distributed according to a normal distribution with mean zero and variance s2d.
As for the matrix SM, it has been shown in the literature that a standard conjugate Wishart
prior is overly influential on the corresponding posterior distribution (see among others [26,
53] and [54]). Moreover, explicitly representing an informative prior distribution for a covari-
ance matrix is difficult. We therefore follow an alternative strategy by adopting a log-Cholesky
parameterization (see [55]) for the precision matrix Σ  1M . More specifically, we define
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Σ  1M ¼ R
>R, with R = {rm,p} being an upper triangular Cholesky factor, with p = 1, . . ., M, m�
p. To guarantee that the Cholesky factorization is unique, one has to require the diagonal ele-
ments of R to be positive. To avoid constrained estimation, we use the logarithms of the diago-
nal elements of R. Hence, the covariance matrix is parameterized in terms of the parameter
vector
β ¼ ð log r1;1; r1;2; log r2;2; r1;3; r2;3; log r3;3; . . . ; log rM;MÞ ð5Þ
Finally, we assume that the components of β, β ℓ with ℓ = 1, . . ., M(M+ 1)/2, are a priori
independent and all distributed according to a normal distribution with zero mean and vari-
ance s2
‘
.
The correlation matrices Γq, with q 2 T are assumed to be independent and uniformly dis-
tributed on the space of all correlation matrices.
Posterior computations
Fig 1 summarizes the formulation of our hierarchical model. Since the joint posterior of the
model parameters cannot be obtained in closed form, we devise a latent variables and adaptive
Markov Chain Monte Carlo (MCMC) algorithm for the posterior inference. At each iteration,
for each unit i (i.e. each study), two sets of latent variables are introduced: the random effects
ðδi2; δi3; . . . ; δiaiÞ and the latent vectors related to the specification of the copula model, xik,
i = 1, . . ., N. Drawing on [45] and [44], we suggest to jointly update all latent variables and the
baseline vectors μi. This is the most delicate step of the algorithm. An adaptive metropolis step
is as well foreseen for the updates of the random effects and the baseline log-odds.
The updates of the copula parameters Γq are obtained by applying the two-stage parameter
expanded reparameterization and Metropolis-Hastings (PX-RPMH) algorithm for simulating
a correlation matrix proposed by [46]. Finally, the full conditionals for d and SM are obtained
from standard results for Bayesian analysis of multiple regression models, an adaptive metrop-
olis step is used for their simulation.
It is worth emphasizing here that the algorithm also allows for the possibility that the out-
comes are reported differently in the studies. In this situation, a simple strategy one can imple-
ment consists in analyzing only the subset of events reported by all studies. Even if this
suggestion allows to bypass the problem, the risk is that a considerable amount of data may be
discarded. In our approach missing data are imputed at each iteration of the algorithm.
A detailed description of devised MCMC algorithm is provided in the Appendix.
Results and discussion
We apply the suggested model to two datasets from two Cochrane reviews. The two datasets
have been analysed based on two different models, so that the performance of our model can
be assessed and compared against two different approaches. In both cases we assume that the
studies share the same Gaussian copula correlation matrix Γ and diffuse priors are chosen for
all parameters by setting in particular s2
m
and s2d equal to 10
3 and s2
‘
equal to 101/8. In both
cases not all outcomes are investigated in all studies. Missing outcomes value yikm are imputed
at each iteration of the algorithm, by imputing the corresponding latent variable value xikm,
from the model predictive distribution. The results come from a long run of the devised algo-
rithm with 350000 iterations of which 300000 are discarded as burn-in. In both cases the con-
vergence of the algorithm is assessed through the R coda package. Both examples can be
reproduced since the corresponding scripts are provided as demos.
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Home safety
In the first example we consider the data from a subset of a Cochrane review of safety educa-
tion and provision of safety equipment for injury prevention, see [56] for a description of the
methods. The focus is on the evidence relating to the prevention of poisoning injuries. Data
come from twenty-two studies on three outcomes are recorded: Medicines Safe storage,
Household Products Safe Storage and Poison Center Number Possession. Nine treatments are
Fig 1. The multiple outcomes network meta-analysis model. The Figure depicts the elements of the suggested
hierachical model.
https://doi.org/10.1371/journal.pone.0231876.g001
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considered: Usual Care (UC), Education (EDU), Education + Provision of free/low cost equip-
ment (EDU+FE), Education + Provision of free/low cost equipment + Fitting of Equipment
(EDU+FE+F), Education + Home Safety Inspection (EDU+HSI), Education + Provision of
free/low cost equipment + Home Safety Inspection Fitting of Equipment (EDU+FE+HSI+F),
Education + Home Visit (EDU + HV), Provision of Free/Low Cost Equipment (FE). Overall
there are three studies considering all three outcomes, nineteen studies considering two out-
comes. All studies but one are two arms. Fig 2 depicts the network graph for the three outcomes.
[51] analyse the same dataset, based on a different approach. Indeed, [51] model the out-
comes log odds ratio so that a continuous, Gaussian, multivariate distribution can be used as
likelihood. Moreover, in [51] the within-study covariances are taken as known, as they are esti-
mated from the data. In our approach, such matrices are assumed to be unknown so that the
model provides as well an estimate of them. The analysis can be replicated by running the
script example_homesafety.R to be found in the folder demo of the netcopula package. Fig 3
displays the trace plots of the pooled treatment effects against the baseline Usual Care.
Fig 2. Home safety: The network structure. The figure shows the network structure: A: Medicines Safe storage, B: Household Products Safe Storage
and C: Poison Center Number Possession. The thicker the lines the higher the number of studies reporting results on the considered outcome.
https://doi.org/10.1371/journal.pone.0231876.g002
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Fig 3. Home safety: Trace plots. The figure shows the trace plots of the pooled treatments effect against the baseline treatment Usual
Care, after discarding the burnin.
https://doi.org/10.1371/journal.pone.0231876.g003
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Tables 1 to 3 display median estimates along with the highest posterior density (HPD) cred-
ibility intervals for the pooled effects estimated according to our model and according to [51],
referred to as Model 3 in the original paper. Usual care is taken as baseline effect. In all cases
our estimates show a smaller variability, in particular in the estimation of the pooled effect of
Education + Home Visit versus Usual Care, of Education + Home Safety Inspection versus
Usual Care and of Provision of Free/Low Cost Equipment versus Usual Care. The EDU+HV
and EDU+HSI are indeed considered only for one outcome and the effect directly compared
against Usual Care. The FE treatment is considered for two outcomes and only indirectly com-
pared against Usual Care. The smaller uncertainty of the median estimates for such treatments
Table 1. Safe storage of medicines: Pooled effects posterior median and HPD 95% credibility intervals.
treatments Copula MONMA Achana et al. MONMA (model 3)
median 2.50% 97.50% median 2.50% 97.50%
EDU-UC 1.81 1.16 3.04 1.32 0.71 2.16
EDU+FE-UC 1.24 0.76 2.14 2.11 1.08 3.94
EDU+FE+HS-UC 1.16 0.82 1.39 1.93 1.06 3.94
EDU+FE+F-UC 1.94 1.02 2.99 1.27 0.68 2.43
EDU+HIS-UC 0.97 0.64 1.60 0.66 0.06 7.09
EDU+FE+HIS+F-UC 0.96 0.51 1.91 2.09 1.13 4.27
EDU+HV-UC 1.47 1.05 2.16 1.42 0.09 14.49
FE+UC 0.64 0.37 1.02 1.75 0.47 5.67
https://doi.org/10.1371/journal.pone.0231876.t001
Table 3. Poison control center telephone number possession: Pooled effects median and HPD 95% credibility intervals.
treatments Copula MONMA Achana et al. MONMA (model 3)
median 2.50% 97.50% median 2.50% 97.50%
EDU-UC 0.94 0.74 1.6 1.32 0.78 2.15
EDU+FE-UC 1.84 1.2 2.7 2.13 1.15 3.91
EDU+FE+HS-UC 1.36 0.82 2.33 1.95 1.12 3.93
EDU+FE+F-UC 0.66 0.37 1.67 1.26 0.67 2.59
EDU+HIS-UC 3.52 2.47 5.32 0.64 0.05 7.97
EDU+FE+HIS+F-UC 3.9 1.36 7.76 2.1 1.14 4.34
EDU+HV-UC 1.97 1.08 3 1.45 0.08 15.13
FE+UC 1.46 0.92 2.14 1.81 0.44 5.52
https://doi.org/10.1371/journal.pone.0231876.t003
Table 2. Safe storage of other household products: Pooled effects median and HPD 95% credibility intervals.
treatments Copula MONMA Achana et al. MONMA (model 3)
median 2.50% 97.50% median 2.50% 97.50%
EDU-UC 1.2 1.00 1.66 1.32 0.78 2.15
EDU+FE-UC 0.97 0.7 1.24 2.13 1.15 3.91
EDU+FE+HS-UC 1.45 0.94 2.32 1.95 1.12 3.93
EDU+FE+F-UC 1.3 0.98 1.67 1.26 0.67 2.59
EDU+HIS-UC 1.23 0.79 1.81 0.64 0.05 7.97
EDU+FE+HIS+F-UC 0.55 0.40 0.81 2.1 1.14 4.34
EDU+HV-UC 0.34 0.20 0.47 1.45 0.08 15.13
FE+UC 0.60 0.38 0.81 1.81 0.44 5.52
https://doi.org/10.1371/journal.pone.0231876.t002
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shows that our model succeeds in borrowing strength across treatments and outcomes as fore-
seen. There are differences in the estimates of the pooled-effects for some treatment compari-
sons. In almost all cases our estimates belong to the corresponding credibility intervals in [51].
A simulation study (not reported here but available as a further demo in the netcopula R pack-
age) shows that, for different settings of the true parameters value, our model is able to recover
the true values of the pooled effects.
Table 4 reports median estimates and highest posterior density (HPD) credibility intervals
for the between-study standard deviations and correlations. Again, the estimates produced by
the fit of our model show a smaller variability especially in the estimation of the within-study
correlations.
Alcohol dependence
In the second example, the data come from a Cochrane systematic review of pharmacology
treatments for alcohol dependency. See [57, 58] for a detailed description of the methods and
[59] for an update. The same data are also analysed in [43]. In particular, the authors model
the outcome correlations resorting to a Clayton copula model, with one single parameter then
fine-tuning such correlations. Moreover they allow for heterogeneity of the random effects.
Again, our analysis can be replicated by running the script example_alcoholdependence.R to
be found in the folder demo of the netcopula package.
The data come from forty-one studies and three outcomes are considered: Return to Heavy
Drinking, Return to Drinking and Discontinuation. Eleven studies consider all three out-
comes, twenty-two studies consider two outcomes and height report results only on one out-
come. Three treatments are considered: naltrexone (NAL), acamprosate (ACA) and
naltrexone + acamprosate (NAL+ACA). Fig 4 depicts the network graph for the three
outcomes.
Tables 5 to 7 reports median estimates along HPD credibility intervals of the treatments
pool effects obtained according to our model and [43] model. We can see that in all cases, our
estimates show a smaller variability. Table 8 reports median estimates and credibility intervals
for the within outcome correlations. Our model estimates a positive weak association between
Return to Drinking and Discontinuation, even if there is high uncertainty on the estimation of
the correlation between Return to Heavy Drinking and Return to Drinking and Return to
Heavy Drinking and Discontinuation.
Conclusion
In this paper we suggest a new model for a multiple outcomes network meta-analysis in the
case of discrete outcomes. Our model accounts for both correlation between outcomes and
Table 4. Between-study standard deviations and correlations.
treatments Copula MONMA Achana et al. MONMA (model 3)
median 2.50% 97.50% median 2.50% 97.50%
σ1 0.58 0.23 1.32 0.23 0.010 1.080
σ2 0.72 0.35 1.42 0.31 0.04 1.18
σ3 1.07 0.57 1.91 1.08 0.57 1.93
ρ12 0.02 -0.7 0.72 0.45 -0.99 1.00
ρ13 0.12 -0.75 0.83 0.5 -0.98 1.00
ρ23 0.40 -0.44 0.86 0.6 -0.87 0.99
https://doi.org/10.1371/journal.pone.0231876.t004
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between treatments. Moreover, we deal with the case of missing at random outcomes. In a
comparison with two approaches previously proposed in the literature our results show a
lower uncertainty. The model we suggest can be extended to the case of outcomes of different
kinds, both discrete and continuous. We use here the Gaussian copula, but the model can be
easily modified to include a different kind of copula.
Fig 4. Alcohol dependence: The network structure. The figure shows the network structure: A: Return to Heavy Drinking, B:
Return to Drinking and C: Discontinuation. The thicker the lines the higher the number of studies reporting results on the
considered outcome.
https://doi.org/10.1371/journal.pone.0231876.g004
Table 5. Return to heavy drinking: Pooled effects posterior median and HPD 95% credibility intervals.
treatments Copula MONMA Liu et al. MONMA
median 2.50% 97.50% median 2.50% 97.50%
NAL-PLB 0.51 0.35 0.69 0.47 0.33 0.62
ACA-PLB 0.73 0.44 1.01 0.68 0.47 0.97
NAL+ACA-PLB 0.5 0.26 0.86 0.5 0.31 0.74
ACA-NAL 1.4 0.89 2.08 1.47 0.99 2.25
NAL+ACA-NAL 0.99 0.53 1.7 1.08 0.64 1.65
NAL+ACA-ACA 0.71 0.39 1.25 0.75 0.43 1.11
https://doi.org/10.1371/journal.pone.0231876.t005
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However, there are some limitations in the suggested approach. The first problem arises in
the estimation of the copula correlation matrix. The algorithm should be improved in order to
reduce the running time and the uncertainty of the derived estimates. In the proposed
approach the correlation matrix is assumed to be unstructured. This in the case of high-dimen-
sional outcome might slow down the convergence of the algorithm. In this case a parametriza-
tion of the correlation matrix might be a reasonable choice as investigated in [60] and [61].
Moreover the performance of the model is particularly affected by the number of studies that
in general is not high. More specifically, our model includes three orders of latent variables,
the variables for the copula, the random effects and the latent variables to be introduced in the
imputation step. The smaller number of studies considered in the first example (22) compared
those in the second example (41) is in our opinions at the basis of the higher uncertainty in the
estimation of the correlation parameters.
Supporting information
S1 Appendix. In the following we provide a description of the algorithm used for fitting
the multiple outcome network meta-analysis model suggested. For the notation, we refer to
Table 7. Discontinuation: Pooled effects posterior median and HPD 95% credibility intervals.
treatments Copula MONMA Liu et al. MONMA
median 2.50% 97.50% median 2.50% 97.50%
NAL-PLB 0.78 0.63 0.97 0.75 0.55 0.99
ACA-PLB 0.8 0.65 0.97 0.81 0.66 1
NAL+ACA-PLB 0.75 0.42 1.28 0.82 0.47 1.4
ACA-NAL 1.03 0.78 1.32 1.1 0.79 1.49
NAL+ACA-NAL 0.96 0.54 1.58 1.1 0.59 1.75
NAL+AC-ACA 0.93 0.53 1.57 1.02 0.58 1.72
https://doi.org/10.1371/journal.pone.0231876.t007
Table 6. Return to drinking: Pooled effects posterior median and HPD 95% credibility intervals.
treatments Copula MONMA Liu et al. MONMA
median 2.50% 97.50% median 2.50% 97.50%
NAL-PLB 0.61 0.44 0.83 0.57 0.41 0.75
ACA-PLB 0.51 0.42 0.59 0.52 0.41 0.65
NAL+ACA-PLB 0.4 0.26 0.6 0.4 0.22 0.64
ACA-NAL 0.83 0.59 1.15 0.94 0.65 1.29
NAL+AC-NAL 0.66 0.4 1.12 0.71 0.37 1.08
NAL+AC-ACA 0.78 0.52 1.25 0.76 0.44 1.25
https://doi.org/10.1371/journal.pone.0231876.t006
Table 8. Alcohol dependence: Within outcomes correlations.
correlations Copula MONMA
median 2.50% 97.50%
Outcome 1—Outcome 2 0.62 -0.13 0.95
Outcome 1—Outcome 3 0.51 -0.23 0.92
Outcome 2—Outcome 3 0.78 0.25 0.96
Outcome 1 is Return to Heavy Drinking, Outcome 2 Return to Drinking and Outcome 3 is Discontinuation.
https://doi.org/10.1371/journal.pone.0231876.t008
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the model depicted in Fig 1.
(PDF)
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